Tactive Advisors’s Moderna MRNA Stock Holding History

Tactive Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,512	Closed	-$1.17M	–	59
2022 Q4	$1.17M	Buy	+6,512	New	+$1.06M	0.76%	24

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Tactive Advisors's MRNA Position: Q1 2023 in Review

Tactive Advisors sold out of Moderna (MRNA) in Q1 2023, closing a stake of 6,512 shares — an estimated $1.17M sold.

Tactive Advisors first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $1.17M in Q4 2022. 1,016 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Tactive Advisors reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Tactive Advisors sold 6,512 Moderna shares in Q1 2023, an estimated $1.17M.
Tactive Advisors first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
Tactive Advisors's Moderna position peaked at $1.17M in Q4 2022.
1,016 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Tactive Advisors's 13F filing for Q1 2023, filed 2 Feb 2024.